3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Endometrial Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Ovarian Epithelial
1
Adenocarcinoma of Lung
1
Interventions
Paclitaxel
6
Carboplatin
6
Radiotherapy
5
Erlotinib Hydrochloride
4
pembrolizumab
3
aldesleukin
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Interleukin-2
2
Cyclophosphamide
2
Bevacizumab
2
veliparib
1
trametinib
1
spartalizumab
1
satraplatin
1
osimertinib
1
onartuzumab
1
nintedanib
1
methyl-4-fluoro-4-deoxyglucose
1
fludarabine phosphate
1
fludarabine
1
bemarituzumab
1
anlotinib
1
aflutinib
1
Taxes
1
Sorafenib
1
Sirolimus
1
Radiotherapy, Conformal
1
Radiosurgery
1
Pentostatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Adenocarcinoma of Lung
×
bemarituzumab
×
Clear all
NCT05325866
2026-02-04
FORTITUDE-301
Amgen
Phase 1/2
Completed
260 enrolled